Flavoxate Hydrochloride Tablets Market to Witness Significant Growth, Owing to High Prevalence of Urinary Incontinence

Flavoxate HCL is a synthetic urinary tract spasmolytic used to treat bladder symptoms such as frequent or urgent urination, increased nighttime urination, bladder pain, and incontinence (urine leakage). According to International Continence Society, in 2018, 63 million people suffered from urgency urinary incontinence worldwide. Such high prevalence of incontinence is expected to aid in growth of the flavoxate hydrochloride tablets market.
High prevalence of urinary tract infections (UTIs) is also expected to aid in growth of the flavoxate hydrochloride tablets market.

According to the study “Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda”, published in February 2019, the prevalence of UTI was 32.2% among the study. Flavoxate HCL is commonly used to treat conditions such as prostatitis, UTIs, and incontinence. The active ingredient is flavonoid glycoside A, which helps by reducing urine flow. The reduced flow enables bacteria that normally live in the bladder to be flushed out with urine.
Flavoxate HCL is sold as Urispas in the flavoxate hydrochloride tablets market.

LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!

Buy Now with Discount for Premium Report (Flat US $ 2000 Off) : https://www.coherentmarketinsights.com/promo/buynow/3384

It is a complex synthetic amino acid that acts by interfering with specific uric acid-producing enzymes in the urinary bladder. It relieves pain, inflammation, urgency, bladder swelling, flatulence, and urinary frequency in most patients with kidney disease (check with your doctor for medical guidance about the proper treatment for your condition). The medication also can effectively prevent the production of new stones in the urinary bladder or reduce the frequency of urination.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3384

The global flavoxate hydrochloride tablets market is expected to witness significant growth during 2020-2027. Increasing geriatric population is one of the major factors for growth of the market during the forecast period. According to United Nations Population Fund, geriatric population in Asia Pacific is expected to triple between 2010 and 2050 to reach 1.3 billion people by 2050.

Several companies are involved in the production and distribution of these tablets. Cipla Inc. is one of the major players in the global market. Their manufacturing facilities are located in North America and Europe. Perrigo Company PLC is another manufacturer that produces and distributes this product. Other companies that operate in the market are Epic Pharma LLC, Recordati S.p.A, Manus Aktteva Biopharma LLP, Trumac Healthcare, Taj Pharmaceuticals Ltd., Zhejiang CONBA Pharmaceutical co., ltd., and Walter Bushnell.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

This release was published on openPR.